A 35-year-old woman diagnosed with multiple myeloma (IgG, type, stage IIIA) received an autologous peripheral blood stem cell transplant (PBSCT). She was euthyroid without autoreactive antibodies prior to the transplant. The patient complained of malaise, weight loss and low grade fever 1 month after transplant, despite rapid haematopoietic recovery. Thyroid function tests on day 34 revealed hyperthyroidism associated with anti-thyroid peroxidase antibody. Antinuclear antibody was also detected, and platelet-associated immunoglobulin was increased. These findings disappeared spontaneously by day 62 without treatment. Autoimmune diseases may occur transiently after autologous PBSCT. Keywords: autoimmune; autologous; peripheral blood stem cells; transplantation; multiple myeloma Stem cell transplantation has been used increasingly for the treatment of multiple myeloma, especially in patients with favorable performance status and adequate organ function. 1 High-dose chemoradiotherapy followed by stem cell transplant has been reported to improve both relapse-free survival and overall survival in myeloma when compared to conventional chemotherapy alone.
1
High-dose chemoradiotherapy followed by stem cell transplant has been reported to improve both relapse-free survival and overall survival in myeloma when compared to conventional chemotherapy alone. 1 Allogeneic bone marrow transplantation (BMT) appears superior to autologous BMT or autologous peripheral blood stem cell transplantation (PBSCT) because of a decreased incidence of relapse. However, transplant-related morbidity and mortality is a major concern with allogeneic BMT. Autologous PBSCT has several advantages over allogeneic BMT, including rapid engraftment and low transplant-related mortality. However, immunologic abnormalities, such as generation of autoreactive antibodies, have been reported in the setting of autologous BMT or PBSCT, similar to allogeneic BMT. 2, 3 We describe a case of autoimmune thyroiditis following autologous PBSCT and discuss the clinical significance of this phenomenon. 
Case report
A 35-year-old woman was diagnosed with multiple myeloma (IgG, type, stage IIIA) by the presence of an M protein in the serum and marked proliferation of myeloma cells (77% of nucleated cells) in the bone marrow. Autoreactive antibodies, including thyroid receptor stimulating antibody, thyroid stimulating hormone (TSH) receptor blocking antibody, TSH receptor stimulating antibody, thyroid peroxidase antibody, and antinuclear antibody were not detected prior to therapy. Two courses of chemotherapy consisting of vincristine, melphalan, ranimustine and dexamethasone led to a marked response, reducing myeloma cells in the bone marrow from 77 to 4.8% and serum ␤2 microglobulin from 4.4 g/ml to 2.4 g/ml. The favorable chemosensitivity and performance status of this patient prompted us to perform an autologous PBSCT. Peripheral blood stem cells (PBSC) were mobilized with cyclophosphamide 2 g/m 2 /day for 2 days, followed by G-CSF 150 g/day; 8.1 × 10 6 CD34-positive cells per kg were collected during recovery. Conditioning consisted of hyperfractionated total body irradiation (TBI) at a dose of 13.2 Gy and melphalan 180 mg/m 2 . Unpurged PBSC were reinfused at transplantation. Regimen-related toxicities including grade 3 neutropenia and grade 2 oral mucositis were well tolerated. Granulocytes exceeded 500/l on day 8, and the last platelet transfusion was on day 9. Thereafter, her clinical course was uneventful until day 30. At that time, the patient presented with fatigue, weight loss and low grade fever. Thyroid function tests on day 34 revealed an elevated free T3 (7.5 pg/ml), free T4 (2.8 ng/ml), and thyroglobulin (114.2 ng/ml), and a severely suppressed TSH level (Ͻ0.03 U/ml) ( Table 1) . Antinuclear (1:160) and anti-thyroid peroxidase antibodies (0.44 U/ml; normal range, Ͻ0.3 U/ml) were detected. Na-123 I scintigram examined under optimal iodine restriction revealed decreased uptake of iodine, confirming the diagnosis of chronic thyroiditis. Ultrasonography showed slight enlargement of the thyroid gland (Rt, 50.5 mm × 17.7 mm × 7.0 mm; Lt, 49.5 mm ×17.7 mm × 10.0 mm). Aspiration cytology did not demonstrate infiltration with lymphocytes. The patient was HLA A 11, A 31, B 39, B 62, DR 15 and DR 8; these haplotypes are not associated with chronic thyroiditis. In addition to thyroid dysfunction, moderate thrombocytopenia (20-30 × 10 9 /l) had persisted following PBSCT, despite abundant megakaryocytes (count; 58/l) in the bone marrow. T cells (absolute number), Ͼ200/l. ANA = antinuclear antibody; PA-IgG = platelet-associated immunoglobulin; NT = not tested.
The level of platelet-associated immunoglobulin (PA-IgG) was increased to 42.6 ng/10 7 cells, suggesting that thrombocytopenia was caused by an autoimmune mechanism. Flow cytometric analysis revealed marked alterations in peripheral CD4, CD8 and CD19 percentages from baseline, changing from 30.8 to 2.4%, from 46.6 to 86.2% and from 2.4 to 0.7%, respectively, at 1 month after transplant (Table 1) . Her symptoms abated and thyroid function and platelet counts improved concurrently with the disappearance of autoreactive antibodies without treatment 2 months after transplant.
Discussion
Endocrine abnormalities have been reported in patients after myeloablative chemoradiotherapy followed by stem cell transplantation. 4, 5 Among pretransplant conditioning regimens, TBI containing regimens strongly affect endocrine function. The thyroid is commonly involved, with most patients developing hypothyroidism. 4, 5 The present patient developed hyperthyroidism with elevations of free T3 and free T4 and suppression of TSH. Detection of antithyroid peroxidase antibody suggests that the hyperthyroidism was caused by autoimmune thyroiditis. Antinuclear antibody detection and PA-IgG elevation, along with chronic thyroiditis, indicate a correlation between autologous PBSCT and generation of autoimmune antibodies, although such autoreactive antibodies can disappear spontaneously. The specificity and exact interpretation of PAIgG remain to be established, although increased levels of PA-IgG have been demonstrated in 80-90% of patients with idiopathic thrombocytopenic purpura. The levels of PA-IgG in our patient changed in parallel with those of antinuclear and antithyroid peroxidase antibodies, suggesting that high levels of PA-IgG and thrombocytopenia may be caused by an autoimmune mechanism.
Several mechanisms are postulated for the generation of autoreactive antibodies after autologous stem cell transplantation. These include modification of self-antigens by viral infection or drugs, cross-reactions between intrinsic antigens and exogenous substances, or dysfunction of the regulatory T cells which appear to be responsible for inactivation of self-reacting T cell clones outside the thymus. 6 In the present case, recovery of CD4-positive cells was delayed after autologous PBSCT. Delayed recovery of regulatory T cells and subsequent reactivation of autoreactive T cells may be the underlying mechanisms for the generation of autoreactive antibodies in this patient, although the precise mechanism remains unknown.
Antitumor effects have been demonstrated in patients who developed autologous GVHD induced by cyclosporine after autologous BMT. 7 Jones et al 8 reported an increase in event-free survival from 40 to 62% and a decrease in relapse from 50 to 29% in aggressive non-Hodgkin's lymphoma patients who developed autologous GVHD. Graftversus-myeloma effect has also been shown in a patient presenting with autologous GVHD. 9 In addition to an antitumor effect, autoreactive antibodies have been detected transiently in patients with autologous GVHD. 3 Moreover, Deliliers et al 2 reported that patients who developed autoreactive antibodies after autologous BMT achieved better long-term survivals. Similar antitumor mechanisms may function in patients with autologous GVHD and in those with autoreactive antibodies. Although cutaneous lesions were not observed in the present case, these immunologic abnormalities may have had a beneficial effect on the patient's disease-free survival.
Systemic autoimmune diseases have recently been treated with high-dose immunosuppressive chemotherapy followed by autologous PBSCT. 10, 11 However, the response is often transient, and a high incidence of recurrence of autoimmune disease has been reported. 11 Removal of autoreactive T cells by depletion or positive selection for CD34-positive cells has been employed to improve outcome. In patients with life-threatening disease, inadequate response to immunosuppressive therapy and adequate organ function, stem cell transplantation may be indicated. Indications for this therapeutic approach in autoimmune diseases should be evaluated with care, since autoimmune disorders may develop after autologous PBSCT, autoimmune thyroiditis and immune-mediated thrombocytopenia having developed in our patient following autologous PBSCT.
